JP2019501935A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501935A5 JP2019501935A5 JP2018536408A JP2018536408A JP2019501935A5 JP 2019501935 A5 JP2019501935 A5 JP 2019501935A5 JP 2018536408 A JP2018536408 A JP 2018536408A JP 2018536408 A JP2018536408 A JP 2018536408A JP 2019501935 A5 JP2019501935 A5 JP 2019501935A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- group
- composition according
- human
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 49
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 208000017169 kidney disease Diseases 0.000 claims 14
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 13
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- -1 CF 3 group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 241000282412 Homo Species 0.000 claims 6
- 125000001931 aliphatic group Chemical group 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 206010018364 Glomerulonephritis Diseases 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000003277 amino group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 108010028780 Complement C3 Proteins 0.000 claims 3
- 102000016918 Complement C3 Human genes 0.000 claims 3
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 229960002051 trandolapril Drugs 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 2
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 claims 2
- 101710101146 Complement factor H-related protein 5 Proteins 0.000 claims 2
- 102100035325 Complement factor H-related protein 5 Human genes 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 229960004530 benazepril Drugs 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 2
- 229960000258 corticotropin Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 230000024924 glomerular filtration Effects 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229960001967 tacrolimus Drugs 0.000 claims 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- XIEWFECSPPTVQN-KMIMAYJXSA-N (2r)-2-[[(2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]py Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC)C(C)C)C1=CC=C(O)C=C1 XIEWFECSPPTVQN-KMIMAYJXSA-N 0.000 claims 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 1
- GHBCIXGRCZIPNQ-MHZLTWQESA-N (3s)-2-(2,2-diphenylacetyl)-6-methoxy-5-phenylmethoxy-3,4-dihydro-1h-isoquinoline-3-carboxylic acid Chemical compound C([C@H](N(CC1=CC=C2OC)C(=O)C(C=3C=CC=CC=3)C=3C=CC=CC=3)C(O)=O)C1=C2OCC1=CC=CC=C1 GHBCIXGRCZIPNQ-MHZLTWQESA-N 0.000 claims 1
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 1
- MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 claims 1
- WRFHGDPIDHPWIQ-UHFFFAOYSA-N 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O=C1N(CC=2C=C(COCC)C(=CC=2)C=2C(=CC=CC=2)S(=O)(=O)NC=2C(=C(C)ON=2)C)C(CCCC)=NC21CCCC2 WRFHGDPIDHPWIQ-UHFFFAOYSA-N 0.000 claims 1
- RGPFEJSMFMFCIT-UHFFFAOYSA-M 2-ethoxy-3-[[4-[2-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate;2-hydroxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCO.CCOC1=NC2=CC=CC(C([O-])=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NC(=O)ON1 RGPFEJSMFMFCIT-UHFFFAOYSA-M 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 239000005485 Azilsartan Substances 0.000 claims 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 claims 1
- 239000003861 C09CA09 - Azilsartan medoxomil Substances 0.000 claims 1
- 102400000739 Corticotropin Human genes 0.000 claims 1
- 101800000414 Corticotropin Proteins 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- 239000005475 Fimasartan Substances 0.000 claims 1
- 108010007859 Lisinopril Proteins 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 108700005633 Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OH Proteins 0.000 claims 1
- 229960000528 amlodipine Drugs 0.000 claims 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 229960002731 azilsartan Drugs 0.000 claims 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 claims 1
- 229960001211 azilsartan medoxomil Drugs 0.000 claims 1
- QJFSABGVXDWMIW-UHFFFAOYSA-N azilsartan medoxomil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C=3NC(=O)ON=3)C(OCC)=NC2=CC=CC=1C(=O)OCC=1OC(=O)OC=1C QJFSABGVXDWMIW-UHFFFAOYSA-N 0.000 claims 1
- 229960003270 belimumab Drugs 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- 229960004349 candesartan cilexetil Drugs 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- PIBARDGJJAGJAJ-NQIIRXRSSA-N danicopan Chemical compound C(C)(=O)C1=NN(C2=CC=C(C=C12)C=1C=NC(=NC1)C)CC(=O)N1[C@@H](C[C@H](C1)F)C(=O)NC1=NC(=CC=C1)Br PIBARDGJJAGJAJ-NQIIRXRSSA-N 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 229960004563 eprosartan Drugs 0.000 claims 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
- 229960003489 fimasartan Drugs 0.000 claims 1
- AMEROGPZOLAFBN-UHFFFAOYSA-N fimasartan Chemical compound CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 AMEROGPZOLAFBN-UHFFFAOYSA-N 0.000 claims 1
- 229960002490 fosinopril Drugs 0.000 claims 1
- 210000005086 glomerual capillary Anatomy 0.000 claims 1
- 229960001195 imidapril Drugs 0.000 claims 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 229940124589 immunosuppressive drug Drugs 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 229960002394 lisinopril Drugs 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- 238000011866 long-term treatment Methods 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- 229960000519 losartan potassium Drugs 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229940015638 narsoplimab Drugs 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 1
- 229960001199 olmesartan medoxomil Drugs 0.000 claims 1
- 229960002582 perindopril Drugs 0.000 claims 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims 1
- 229960003076 perindopril arginine Drugs 0.000 claims 1
- RYCSJJXKEWBUTI-YDYAIEMNSA-N perindopril arginine Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 RYCSJJXKEWBUTI-YDYAIEMNSA-N 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 229960001455 quinapril Drugs 0.000 claims 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 1
- 229960003401 ramipril Drugs 0.000 claims 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 229950002009 sparsentan Drugs 0.000 claims 1
- 229960002909 spirapril Drugs 0.000 claims 1
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 claims 1
- 108700035424 spirapril Proteins 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- 229960004084 temocapril Drugs 0.000 claims 1
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
- 229960001722 verapamil Drugs 0.000 claims 1
- 229960002769 zofenopril Drugs 0.000 claims 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 claims 1
- 0 C*c(c(C(F)(F)F)c1)ccc1N(CCC(CCC1)C(C2=CC3)N1C(c1c(C*)cccc1I)=O)C2=CC3NC1CCCC1 Chemical compound C*c(c(C(F)(F)F)c1)ccc1N(CCC(CCC1)C(C2=CC3)N1C(c1c(C*)cccc1I)=O)C2=CC3NC1CCCC1 0.000 description 2
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021129774A JP7788814B2 (ja) | 2016-01-14 | 2021-08-06 | Ｃ３腎症を処置する方法 |
| JP2023100664A JP2023126235A (ja) | 2016-01-14 | 2023-06-20 | Ｃ３腎症を処置する方法 |
| JP2024092498A JP2024110998A (ja) | 2016-01-14 | 2024-06-06 | Ｃ３腎症を処置する方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662278788P | 2016-01-14 | 2016-01-14 | |
| US62/278,788 | 2016-01-14 | ||
| US201662280346P | 2016-01-19 | 2016-01-19 | |
| US62/280,346 | 2016-01-19 | ||
| US201662347450P | 2016-06-08 | 2016-06-08 | |
| US62/347,450 | 2016-06-08 | ||
| US201662397527P | 2016-09-21 | 2016-09-21 | |
| US62/397,527 | 2016-09-21 | ||
| PCT/US2017/013132 WO2017123716A1 (en) | 2016-01-14 | 2017-01-12 | Method of treating c3 glomerulopathy |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021129774A Division JP7788814B2 (ja) | 2016-01-14 | 2021-08-06 | Ｃ３腎症を処置する方法 |
| JP2023100664A Division JP2023126235A (ja) | 2016-01-14 | 2023-06-20 | Ｃ３腎症を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501935A JP2019501935A (ja) | 2019-01-24 |
| JP2019501935A5 true JP2019501935A5 (enExample) | 2020-02-20 |
| JP7339733B2 JP7339733B2 (ja) | 2023-09-06 |
Family
ID=59312069
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018536408A Active JP7339733B2 (ja) | 2016-01-14 | 2017-01-12 | Ｃ３腎症を処置する方法 |
| JP2021129774A Active JP7788814B2 (ja) | 2016-01-14 | 2021-08-06 | Ｃ３腎症を処置する方法 |
| JP2023100664A Pending JP2023126235A (ja) | 2016-01-14 | 2023-06-20 | Ｃ３腎症を処置する方法 |
| JP2024092498A Withdrawn JP2024110998A (ja) | 2016-01-14 | 2024-06-06 | Ｃ３腎症を処置する方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021129774A Active JP7788814B2 (ja) | 2016-01-14 | 2021-08-06 | Ｃ３腎症を処置する方法 |
| JP2023100664A Pending JP2023126235A (ja) | 2016-01-14 | 2023-06-20 | Ｃ３腎症を処置する方法 |
| JP2024092498A Withdrawn JP2024110998A (ja) | 2016-01-14 | 2024-06-06 | Ｃ３腎症を処置する方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20170202821A1 (enExample) |
| EP (1) | EP3402486B1 (enExample) |
| JP (4) | JP7339733B2 (enExample) |
| KR (1) | KR102767008B1 (enExample) |
| CN (1) | CN108601790B (enExample) |
| AU (1) | AU2017207359C1 (enExample) |
| BR (2) | BR112018014222A2 (enExample) |
| CA (1) | CA3010735C (enExample) |
| ES (1) | ES3026359T3 (enExample) |
| IL (1) | IL260539B (enExample) |
| MA (1) | MA43872A (enExample) |
| MX (2) | MX2022006069A (enExample) |
| NZ (1) | NZ744083A (enExample) |
| RU (1) | RU2742888C2 (enExample) |
| SG (1) | SG11201805828YA (enExample) |
| TW (1) | TWI791423B (enExample) |
| WO (1) | WO2017123716A1 (enExample) |
| ZA (1) | ZA201804513B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202200074T1 (it) | 2008-12-22 | 2022-03-21 | Chemocentryx Inc | Antagonisti di c5ar |
| HRP20171176T1 (hr) | 2010-06-24 | 2017-10-06 | Chemocentryx, Inc. | C5ar antagonisti |
| EP3682879B1 (en) | 2014-09-29 | 2022-08-03 | ChemoCentryx, Inc. | Processes and intermediates in the preparation of c5ar antagonists |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| MX2022006069A (es) | 2016-01-14 | 2023-01-12 | Chemocentryx Inc | Metodo para tratar glomerulopatia c3. |
| KR102632860B1 (ko) | 2017-03-01 | 2024-02-02 | 아칠리온 파르마세우티칼스 인코포레이티드 | 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| EP3661493A4 (en) | 2017-08-02 | 2021-04-14 | Achillion Pharmaceuticals, Inc. | THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA |
| JP2020529227A (ja) * | 2018-01-30 | 2020-10-08 | プロクター アンド ギャンブル インターナショナル オペレーションズ エスエーＰｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｏｐｅｒａｔｉｏｎｓ Ｓａ | 懸濁粒子を含む相安定で噴霧可能なフレッシュニング組成物 |
| EP3814374A4 (en) * | 2018-05-25 | 2022-03-09 | Achillion Pharmaceuticals, Inc. | NEPHROPATHY BIOMARKERS ASSOCIATED WITH COMPLEMENT ALTERNATIVE PATHWAY |
| EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| US11814363B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Morphic forms of danicopan |
| EP3856164B1 (en) | 2018-09-25 | 2024-08-07 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| EP4487915A3 (en) | 2018-11-30 | 2025-03-19 | ChemoCentryx, Inc. | Capsule formulations |
| BR112021011727A2 (pt) | 2018-12-17 | 2021-08-31 | Achillion Pharmaceuticals, Inc | Dosagem direcionada para o tratamento de distúrbios mediados do complemento |
| CN113784955B (zh) | 2019-03-11 | 2025-02-14 | 因弗拉克斯有限责任公司 | 作为C5a受体调节剂的稠合哌啶基双环和相关化合物 |
| WO2020198062A1 (en) | 2019-03-22 | 2020-10-01 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| AU2021321901A1 (en) * | 2020-08-07 | 2023-03-09 | Kira Pharmaceuticals (Suzhou) Ltd. | Compounds as C5ar inhibitors |
| AU2021410668A1 (en) * | 2020-12-21 | 2023-07-06 | Chemocentryx, Inc. | Treatment of c3 glomerulopathy using a c5a inhibitor |
| CN115192563B (zh) * | 2022-05-09 | 2023-10-13 | 北京大学第一医院 | C3a/C3aR通路拮抗剂治疗原发性膜性肾病的用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| AU772477B2 (en) | 1998-08-28 | 2004-04-29 | Scios Inc. | Inhibitors of p38-alpha kinase |
| RU2197288C2 (ru) * | 1999-08-03 | 2003-01-27 | Тверская медицинская академия | Способ лечения больных хроническим гломерулонефритом |
| US6713502B2 (en) | 2000-05-05 | 2004-03-30 | Smithkline Beecham Corporation | Anti-infectives |
| CN1231464C (zh) | 2000-08-10 | 2005-12-14 | 三菱制药株式会社 | 新型3－取代的脲衍生物及其药学应用 |
| WO2002022556A1 (en) | 2000-09-14 | 2002-03-21 | Mitsubishi Pharma Corporation | Novel amide derivatives and medicinal use thereof ugs |
| DE60039921D1 (de) | 2000-09-29 | 2008-09-25 | Neurogen Corp | Hochaffine kleinmolekülige c5a-rezeptor-modulatoren |
| CA2457461C (en) | 2001-08-17 | 2013-12-24 | Tanox, Inc. | Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
| ES2323576T3 (es) | 2001-09-21 | 2009-07-21 | Mitsubishi Tanabe Pharma Corporation | Derivados de 4-pirimidona 3-sustituida. |
| ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| WO2003082828A1 (en) | 2002-03-28 | 2003-10-09 | Neurogen Corporation | Substituted tetrahydroisoquinolines as c5a receptor modulators |
| AU2003225971A1 (en) | 2002-03-28 | 2003-10-13 | Yang Gao | Substituted biaryl amides as c5a receptor modulators |
| JP2005530719A (ja) | 2002-03-29 | 2005-10-13 | ニューロジェン コーポレーション | 病原性炎症要素を有する状態の治療のための組み合わせ療法 |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| EP1529046A1 (en) | 2002-08-08 | 2005-05-11 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted benzimidazole compounds |
| US7169775B2 (en) | 2002-08-21 | 2007-01-30 | Neurogen Corporation | Amino methyl imidazoles as C5a receptor modulators |
| US7455837B2 (en) | 2002-11-05 | 2008-11-25 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
| FR2846654A1 (fr) | 2002-11-05 | 2004-05-07 | Servier Lab | Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ATE552253T1 (de) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
| AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
| EP1638935A1 (en) | 2003-06-19 | 2006-03-29 | Pfizer Products Inc. | Nk1 antagonist |
| WO2005007087A2 (en) | 2003-07-03 | 2005-01-27 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| EA200700117A1 (ru) | 2004-06-24 | 2007-06-29 | Инсайт Корпорейшн | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов |
| US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| NZ561613A (en) | 2005-02-18 | 2010-12-24 | Astrazeneca Ab | Antibacterial piperidine derivatives |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US20070112015A1 (en) | 2005-10-28 | 2007-05-17 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
| RS55192B1 (sr) | 2005-11-24 | 2017-01-31 | Dompé Farm S P A | Derivati (r)-arilkilamina i farmaceutske kompozicije koje ih sadrže |
| ES2965283T3 (es) * | 2006-03-15 | 2024-05-28 | Alexion Pharma Inc | Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento |
| WO2008022060A2 (en) | 2006-08-14 | 2008-02-21 | Novartis Ag | Imidazo-pyridine derivatives for modulating protein kinase activity |
| EP2077842A2 (en) * | 2006-10-31 | 2009-07-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an egfr antagonist for the treatment of glomerolonephritis |
| US20100190824A1 (en) | 2007-06-29 | 2010-07-29 | Prabhat Kumar | Novel Substituted Piperidones as HSP Inducers |
| AU2009282480B2 (en) | 2008-08-11 | 2015-05-07 | Children's Medical Center Corporation | Halofuginone analogs for inhibition of tRNA synthetases and uses thereof |
| WO2010025510A1 (en) | 2008-09-03 | 2010-03-11 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
| US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
| US9447176B2 (en) | 2008-11-10 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| SMT202200074T1 (it) | 2008-12-22 | 2022-03-21 | Chemocentryx Inc | Antagonisti di c5ar |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| US20120252792A1 (en) | 2009-09-17 | 2012-10-04 | The Regents Of The University Of Michigan | Methods and compositions for modulating rho-mediated gene transcription |
| HRP20171176T1 (hr) | 2010-06-24 | 2017-10-06 | Chemocentryx, Inc. | C5ar antagonisti |
| US8147400B1 (en) * | 2011-01-17 | 2012-04-03 | Coloplast A/S | Penile implant with dilatant liquid |
| AU2013277154A1 (en) * | 2012-06-20 | 2014-12-18 | Jonathan E. Grob | Complement pathway modulators and uses thereof |
| DK2994488T3 (da) | 2013-05-08 | 2022-10-03 | Novo Nordisk As | Anvendelse af c5ar-antagonister |
| EP3682879B1 (en) | 2014-09-29 | 2022-08-03 | ChemoCentryx, Inc. | Processes and intermediates in the preparation of c5ar antagonists |
| MX2022006069A (es) | 2016-01-14 | 2023-01-12 | Chemocentryx Inc | Metodo para tratar glomerulopatia c3. |
| WO2017176620A2 (en) | 2016-04-04 | 2017-10-12 | Chemocentryx, Inc. | SOLUBLE C5aR ANTAGONISTS |
| AU2021410668A1 (en) | 2020-12-21 | 2023-07-06 | Chemocentryx, Inc. | Treatment of c3 glomerulopathy using a c5a inhibitor |
-
2017
- 2017-01-12 MX MX2022006069A patent/MX2022006069A/es unknown
- 2017-01-12 JP JP2018536408A patent/JP7339733B2/ja active Active
- 2017-01-12 CA CA3010735A patent/CA3010735C/en active Active
- 2017-01-12 MA MA043872A patent/MA43872A/fr unknown
- 2017-01-12 WO PCT/US2017/013132 patent/WO2017123716A1/en not_active Ceased
- 2017-01-12 NZ NZ744083A patent/NZ744083A/en unknown
- 2017-01-12 KR KR1020187023360A patent/KR102767008B1/ko active Active
- 2017-01-12 EP EP17738902.0A patent/EP3402486B1/en active Active
- 2017-01-12 US US15/404,610 patent/US20170202821A1/en not_active Abandoned
- 2017-01-12 MX MX2018008624A patent/MX2018008624A/es unknown
- 2017-01-12 BR BR112018014222-0A patent/BR112018014222A2/pt not_active Application Discontinuation
- 2017-01-12 BR BR122024002810-7A patent/BR122024002810A2/pt not_active Application Discontinuation
- 2017-01-12 ES ES17738902T patent/ES3026359T3/es active Active
- 2017-01-12 AU AU2017207359A patent/AU2017207359C1/en active Active
- 2017-01-12 TW TW106100938A patent/TWI791423B/zh active
- 2017-01-12 CN CN201780006962.XA patent/CN108601790B/zh active Active
- 2017-01-12 SG SG11201805828YA patent/SG11201805828YA/en unknown
- 2017-01-12 RU RU2018129378A patent/RU2742888C2/ru active
-
2018
- 2018-07-06 ZA ZA2018/04513A patent/ZA201804513B/en unknown
- 2018-07-11 IL IL260539A patent/IL260539B/en active IP Right Grant
- 2018-11-08 US US16/184,535 patent/US11285138B2/en active Active
-
2021
- 2021-08-06 JP JP2021129774A patent/JP7788814B2/ja active Active
-
2022
- 2022-02-14 US US17/670,604 patent/US11779576B2/en active Active
-
2023
- 2023-06-20 JP JP2023100664A patent/JP2023126235A/ja active Pending
-
2024
- 2024-06-06 JP JP2024092498A patent/JP2024110998A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018129378A (ru) | Способ лечения с3-гломерулопатии | |
| US20230346927A1 (en) | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | |
| AU2016212230B2 (en) | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | |
| CN107864625B (zh) | 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品 | |
| JP2020536919A5 (enExample) | ||
| US20240277661A1 (en) | Methods of treating apol-1 dependent focal segmental glomerulosclerosis | |
| JP2018507244A5 (enExample) | ||
| RU2020113612A (ru) | Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2 | |
| EA032028B1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| JP2017524702A5 (enExample) | ||
| AU2007235576A1 (en) | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | |
| CA3162624A1 (en) | Biomarkers for cancer therapy using mdm2 antagonists | |
| EP3423057A1 (en) | Compositions and combinations of autotaxin inhibitors | |
| JP2025532929A (ja) | Ｎ－（５－置換－［（１，３，４－チアジアゾリル）または（１，３－チアゾリル）］（置換）カルボキサミド化合物、医薬組成物、ならびにアミド化合物の調製及びその使用の方法 | |
| JP2020515600A (ja) | 抗がん併用療法 | |
| EP2425830A1 (en) | Synergistic drug combination for the treatment of cancer | |
| US20240173403A1 (en) | Combination of AXL Antibodies and ACE Inhibitors in the Treatment of Fibrosis | |
| KR20220128622A (ko) | Ahr-억제제 및 pd1-억제제 항체의 조합물 및 암 치료에서의 그의 용도 | |
| EP3866805A1 (en) | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds | |
| KR20250044436A (ko) | Cdk7 억제제와 기타 항암 치료제의 병용 치료 | |
| WO2021260443A1 (en) | Combinations of 2,3-dihydroimidazo[1,2-c]quinazolines | |
| EA050146B1 (ru) | Способы лечения apol-1-зависимого фокально-сегментарного гломерулосклероза | |
| OA21335A (en) | Methods of treating APOL-1 dependent focal segmental glomerulosclerosis. | |
| CA3068324A1 (en) | Combination of a pi3k-inhibitor with an androgen receptor antagonist | |
| WO2015175008A1 (en) | Methods of treating chronic kidney disease characterized by macroalbuminuria |